Table 2. Comparable outcomes of included colorectal cancer screening (CRCS) studies.
| Study | Eligibility rate for programme (approached patients, eligible patients) | Eligibility rate for screening (patients signing up for programme, eligible for screening) | Participation rate (eligible for screening, kit issued) | Completion rate (returned kit, issued kit) | Screening test positivity rate (positive kit, issued kit) | Diagnostic test positivity rate (positive colonoscopy, positive screening tests) | Detection rates |
| Pharmacy-based CRCS | |||||||
| Holle et al 28 | 5 | 50 | 88 | 100 | 14 | 0 | — |
| Flaherty and Farrelly 27 | — | 81 | 100 | 74 | — | — | — |
| Le Duff et al 29 | — | — | 36 | 36 | 6 | 13 | — |
| Ruggli et al 30 | — | 97 | 97 | — | 7 | Incomplete data | Incomplete data |
| Usual care is pharmacy-based CCRS | |||||||
| Burón 31 | n/a | n/a | — | 44 | 6 | — | Low-risk adenoma 9‰; high-risk adenoma 22‰; invasive cancer 3‰ |
| Vives et al 39 | n/a | n/a | 40 | 94 | — | — | — |
| Parente et al 36 | — | Eligible people, n: 80 915 | — | — | — | — | Cancers detected via screening, n: 95 |
| Chiereghin et al 33 | — | — | 62a | 94–97b | — | — | — |
| Mancini et al 35 | — | — | 53c | — | — | — | — |
| Stoffel et al 38 | — | — | 36 | — | — | — | — |
Data are % unless otherwise indicated. a62% after, vs prior to pharmacy integration into the screening programme 57%. bIn 2 consecutive years. cResponse rate: 53% (PCC 52%, mailing 50%). n/a = not applicable. PCC = Primary Care Centre.